|Year : 2009 | Volume
| Issue : 3 | Page : 125-128
Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats
Anil Pareek1, PG Yeole2, CR Tenpe2, Nitin Chandurkar1, Ravikiran Payghan1
1 Department of Medical Affairs and Clinical Research, Ipca Laboratories Ltd., 142 AB, Kandivli Industrial Estate, Kandivli (West), Mumbai - 400 067, India
2 Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha, Maharashtra - 442 001, India
|Date of Submission||31-Dec-2007|
|Date of Decision||22-Feb-2008|
|Date of Acceptance||06-Jun-2009|
|Date of Web Publication||28-Aug-2009|
Department of Medical Affairs and Clinical Research, Ipca Laboratories Ltd., 142 AB, Kandivli Industrial Estate, Kandivli (West), Mumbai - 400 067
Source of Support: None, Conflict of Interest: None
Objective: To evaluate the antihyperglycemic activity of atorvastatin and hydroxychloroquine combination in alloxan-induced diabetic rats.
Materials and Methods: Alloxan induced diabetic Wistar male rats were randomized into six groups of 6 rats each. (Normal rats, diabetic control, atorvastatin (ATV), hydroxychloroquine (HCQ), ATV 5 mg /kg + HCQ 100 mg/kg, and ATV 10 mg/kg + HCQ 200 mg/kg). The rats were treated for 9 days and blood samples were collected at baseline and end of therapy. These samples were analyzed for plasma glucose by autoanalyzer. Changes in body weight, water, food intakes and total protein content were also recorded.
Results: Atorvastatin and hydroxychloroquine alone and in combination reported significant fall in blood glucose level from baseline. Fall in glucose level was significantly more in high dose combination of atorvastatin and hydroxychloroquine (ATV: 10 mg/kg + HCQ: 200 mg/kg) as compared to other study treatment groups (ATV: 17% Vs HCQ: 7% Vs ATV 5mg/kg + HCQ 100mg /kg: 14% Vs ATV 10mg/kg + HCQ 200mg /kg: 21%; p<0.01). ATV and HCQ individually and in combination also improved the body weight loss. The weight gain was significantly more in combination treated rats as compared to positive control group and greater than those who received atorvastatin and hydroxychloroquine alone. Rats treated with the combination also reported significant decrease in food intake and significant increase in total protein.
Conclusion: Increased hypoglycemic effect in combination may be due to potentiation or synergism between HCQ and ATV. Further studies are required to demonstrate clinically significant antidiabetic effect.
Keywords: Antihyperglycemic activity, alloxan, atorvastatin, hydroxychloroquine, plasma glucose
|How to cite this article:|
Pareek A, Yeole P G, Tenpe C R, Chandurkar N, Payghan R. Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats. Indian J Pharmacol 2009;41:125-8
|How to cite this URL:|
Pareek A, Yeole P G, Tenpe C R, Chandurkar N, Payghan R. Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats. Indian J Pharmacol [serial online] 2009 [cited 2020 Aug 12];41:125-8. Available from: http://www.ijp-online.com/text.asp?2009/41/3/125/55213
| » Introduction|| |
Diabetes mellitus is a principal cause of morbidity and mortality in man population.  Diabetes currently affects an estimated 15.1 million people in North America, 18.5 million in Europe, 51.4 million in Asia, and just under 1 million in Oceania.  It is estimated that globally, the number of diabetic patients will rise from 151 million in the year 2000,  to 221 million by the year 2010, and to 300 million by 2025.  Atherosclerosis is the most common cause of death in diabetes mellitus. An ideal oral treatment for diabetes would be a drug that not only controls the glucose level but also prevents the development of atherosclerosis and other complications of diabetes. Unfortunately, among the currently available drugs, the choice is very limited. Alloxan monohydrate is known for its selective pancreatic islet beta cell cytotoxicity and has been extensively used to induce diabetes mellitus in animals.
Hydroxychloroquine is an antimalarial drug that also acts as a disease-modifying agent in rheumatoid arthritis and lupus erythematosus.  The mechanism by which hydroxychloroquine improves hyperglycemia remains unclear. In vitro evidence has shown that chloroquine reduces intracellular insulin degradation; increases intracellular insulin accumulation, slows receptor recycling and stimulates insulin-mediated glucose transport. 
In an experimental study, hydroxychloroquine significantly elevated insulin-blood concentration resulting in reduced glucose levels in a concentration dependent fashion in diabetic rats.  Clinically, hydroxychloroquine showed improvement in sulphonylurea refractory patients with poorly controlled Type 2 diabetes.  In another prospective, multicentric observational study of 4905 adults with rheumatoid arthritis, diabetes was reported in 54 patients who had taken hydroxychloroquine as compared to 171 patients who had never taken hydroxychloroquine. It was thus concluded that among patients with rheumatoid arthritis, use of hydroxychloroquine is associated with a reduced risk of diabetes. 
Atorvastatin (ATV) is a selective, competitive inhibitor of HMG-CoA reductase used in patients with diabetes and hypercholesterolemia and has been found to be safe and effective.  In previous animal study atorvastatin inhibited increase in plasma glucose level and in clinical studies, patients with type II diabetes mellitus exhibited significant decrease in HbA1c level after treatment with atorvastatin.  Based on these evidences the present study was planned to demonstrate that combination of atorvastatin and hydroxychloroquine may give better glycemic control along with improved lipid profile.
The objective of the present study was to evaluate the effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats.
| » Materials and Methods|| |
Alloxan monohydrate (Sigma Chemical Company), atorvastatin and hydroxychloroquine (Ipca Laboratories Ltd., Mumbai) were used in the study. All other chemicals were obtained from local sources and were of analytical grade.
Wistar male rats weighing 150-200 g were procured from the Laboratory Animal Resource Section of Institute of Pharmaceutical Education and Research, Wardha, India. The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage and acclimatized for a period of 7 days. Individual animal was identified by a mark on tail with permanent marker and cages were identified with label pasted on cages with relevant information. Animals were housed at a temperature of 24 + 2 o C and relative humidity of 30 to 70%. A 12:12 hr light: dark cycle was followed. All animals had free access to water and standard pelleted laboratory animal diet. The male animals were selected for the studies since the females are shown to be protected from lipid-induced reductions in insulin actions.  The experimental protocol was approved by the Institutional Animal Ethics Committee.
Preparation and administration of drugs
The ATV and HCQ were suspended in vehicle (0.1% w/v suspension of Tween 80 and carboxymethylcellulose (CMC) in water). Animals were deprived of food for 2 hr before dosing. ATV (10 mg/kg) and HCQ (200 mg/kg) were administered in a single dose orally by gavage using a syringe fitted with suitable sized canula. Actual amount was decided on body weight basis. Volume of formulation administered was 0.2 ml per 150 g body weight. After administration animals were fasted for 1 hr.
Induction of experimental diabetes
Experimental diabetes was induced in rats by injecting alloxan monohydrate intraperitoneally at a dose of 90 mg/kg body weight  Alloxan was dissolved in citrate buffer at pH 4.5 and injected immediately within few minutes to avoid degradation. After 72 hr, blood was collected from the retro-orbital plexus by chloroform anaesthesia of all surviving rats and blood glucose levels were determined using autoanalyser (Microlab 2000). Rats with blood sugar level of 200-350 mg/dl, as well as with polydipsia, polyuria, and polyphagia were considered as diabetic and were employed in the study.
The rats were randomly divided into six groups consisting of six rats each. Group 1 (normal control) consisted of normal rats that neither received alloxan monohydrate nor any drug. Group 2 served as positive control (diabetic control). Rats in Group 3 were diabetic and treated with atorvastatin (10 mg/kg;p.o.). Rats in Group 4 were diabetic and treated with hydroxychloroquine (200 mg/kg;). Animals in Group 5 were diabetic and treated with combination of low dose atorvastatin (5mg/kg; p.o.) and hydroxychloroquine (100mg/kg;p.o.), whereas diabetic rats in Group 6 were treated with combination of atorvastatin (10mg/kg p.o.) and hydroxychloroquine (200mg/kg;p.o.). The drugs were given once daily for 9 days. th
Estimation of plasma glucose and total protein
Blood samples were collected from 18 hr fasted rats at 1 hr after the last dose administration from the retro-orbital plexus under chloroform anesthesia and analyzed for plasma glucose by autoanalyzer (Microlab 2000). Total protein content was also estimated by using autoanalyzer (Microlab 2000). In addition, the changes in body weight, water and food intakes and total protein content were recorded in both the control and treated groups.
The results were expressed as mean ± SD. All the data were analyzed by one way analysis of variance followed by Dunnett's t-test. A value of P < 0.05 was considered as statistically significant.
| » Results|| |
Effects on body weight, water and food intakes
The effect of ATV and HCQ individually and in combination on body weight, food and water intake were assessed for nine days. Alloxan-induced diabetic rats showed marked decrease in body weight. There was considerable increase in water and food intake. ATV (10 mg/kg; p.o.) with HCQ (200 mg/kg; p.o.) significantly ( P <0.01) improved the body weight as compared to diabetic control [Table 1]. There was no significant ( P >0.05) change in water intake in normal, diabetic and diabetic treated rats. Diabetic rats showed significant increase in food intake as compared to normal rats. ATV (10 mg/kg; p.o.) and HCQ (200 mg/kg; p.o.) individually showed non significant decrease in food intake ( P >0.05). However, the combination of ATV and HCQ showed significant decrease in food intake at both doses.
Effect on plasma glucose level
[Table 2] shows the result of blood glucose values in alloxan induced diabetic rats after a daily treatment with ATV and HCQ individually and in combination for nine days. ATV, at a dose of 10 mg/kg, showed significant decrease in the blood glucose levels of 17%, whereas HCQ at a dose of 200 mg/kg showed 7% decrease in blood glucose level. In combination, ATV (5 mg/kg) and HCQ (100 mg/kg) showed 14 % reduction in blood glucose level. The combination of ATV (10 mg/kg) and HCQ (200 mg/kg) exhibited the maximum (21%) reduction in glucose level.
Effect on plasma protein level
[Table 3] shows the results of plasma protein levels in alloxan induced diabetic rats after a daily treatment with ATV and HCQ individually and in combination for nine days. Administration of ATV (10 mg/kg) and HCQ (200 mg/kg) individually resulted into an increase of total protein in diabetic rats by 5% and 13%, respectively. In combination, ATV (5 mg/kg) and HCQ (100 mg/kg) showed highly significant increase in total protein level by 24% whereas combination of ATV (10mg/kg) and HCQ (200mg/kg) showed the maximum increase in total protein level by 40%.
| » Discussion|| |
Diabetes mellitus is a disease characterized by elevated blood glucose levels, resulting from absence or inadequate pancreatic insulin secretion.  The prevalence of diabetes is increasing worldwide. Insulin resistance plays a key role in the development of the disease in about 90% of patients with NIDDM. The researchers examined the hydroxychloroquine, a commonly used medication to treat rheumatoid arthritis, for its hypoglycemic effects.  In animal models, hydroxychloroquine showed significantly elevated insulin blood concentration resulting in reduced glucose levels in streptozotocin induced diabetic rats. 
In addition to hyperglycemia, patients with type 2 diabetes often present with a concomitant atherogenic dyslipidemia (elevated triglycerides, low HDL cholesterol, and elevated LDL cholesterol) that increases risk of cardiovascular disease. , Because there is a high incidence of mortality for type 2 diabetics with their first myocardial infarction, aggressive therapy for treating diabetic dyslipidemia is recommended. 
Atorvastatin (ATV) is a selective, competitive inhibitor of HMG-CoA reductase used in patients with diabetes and hypercholesterolemia and has been found to be safe and effective. In animal model of type II diabetes mellitus, atorvastatin exerts significant lipid lowering effect, glucose lowering effect and decreased plasma insulin levels and insulin resistance index. Atorvastatin may improve insulin resistance.
In the present study, we investigated the antihyperglycemic activity of atorvastatin and hydroxychloroquine when administered alone and in combination in alloxan induced diabetic rats. Both, atorvastatin and hydroxychloroquine when administered alone and in low dose and in high dose combination orally for nine days showed significant decrease in the blood glucose levels. Interestingly, the high dose combination of atorvastatin and hydroxychloroquine exhibited the most significant reduction in glucose level than their low dose combination and when administered alone. Thus, the antihyperglycemic effect reported by hydroxychloroquine in streptozotocin-diabetic rats  and atorvastatin in KK/Ay mice  was further confirmed in our study.
Alloxan-monohydrate caused body weight reduction that was reversed by combination of atorvastatin (10 mg/kg) and hydroxychloroquine (200 mg/kg) indicating that the combination has beneficial effect in preventing loss of body weight in diabetic rats. [Table 1] The combination has also shown significant decrease in food intake.
Diabetes mellitus is characterized by dysregulation in carbohydrate, fat and protein metabolism. In present study the combination has shown significant increase in the total protein content in alloxan induced diabetic rats. This shows that the combination has improved the protein metabolism.
Along with antihyperglycemic effects, hydroxychloroquine is also associated with cardiovascular benefits. Improvement of serum cholesterol in patients treated with hydroxychloroquine has been reported. These include a decrease in serum cholesterol by approximately 10% and an increase in low-density lipoprotein receptors. Hydroxychloroquine also led to a rise in both HDL and %HDL. 
Atorvastatin with hydroxychloroquine can offer a new and promising approach in the management of diabetes mellitus, due to its multifaceted action. Since the combination can produce a better glycemic control along with improvement in the lipid profile in animals, it is worthwhile to evaluate the combination of atorvastatin and hydroxychloroquine at different doses so as to find out the potential of this combination as an antidiabetic therapy. Well controlled clinical studies are required to demonstrate this anti diabetic effect.
| » Conclusion|| |
The present study demonstrates that combination of hydroxychloroquine with atorvastatin at the dose level tested exhibits significant glucose lowering activity in alloxan induced diabetic rats. Increased effect in combination may be due to potentiation or synergism.
| » Acknowledgement|| |
This study was sponsored by Ipca Laboratories Limited. The authors would like to thank Mr. B. V. Ghule, Mr. A. M. Patole and Mr. L. G. Rathi for providing all the technical support for undertaking this research work.
| » References|| |
|1.||Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12. [PUBMED] [FULLTEXT]|
|2.||Benny K, Chee HT, Peter NP. Anti-diabetic activity of the semi-purified fractions of Averrhoa bilimbi in high fat diet fed-streptozotocin-induced diabetic rats. Life Sciences 2005;76:2827-39. |
|3.||Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14:S1-85. |
|4.||King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 1998;21: 1414-31. [PUBMED] [FULLTEXT]|
|5.||Morand EF, McCloud PI, Littlejohn GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1992;51:1318-21. [PUBMED] [FULLTEXT]|
|6.||Emami J, Pasutto FM, Mercer JR, Jamali F. Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sciences 1999;64:325-35. [PUBMED] [FULLTEXT]|
|7.||Emami J, Gerstein HC, Pasutto FM, Jamali F. Insulin sparing effect of HCQ in diabetic rats is concentration dependent. Can J Physiol Pharmacol 1999;77:118-23. [PUBMED] [FULLTEXT]|
|8.||Hertzel C. Gerstein, Kevin E. Thorpe, D Wayne Taylor, R. Brian Haynes. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylurea-a randomized trial. Diabetes Res Clin Pract 2002;55:209-19. |
|9.||Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007;298:187-93. [PUBMED] [FULLTEXT]|
|10.||Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. |
|11.||Suzuki M, Kakuta H, Takahashi A, Shimano H, Tada-Iida K, Yokoo T, et al. Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. J Atheroscler Thromb 2005;12:77-84. [PUBMED] [FULLTEXT]|
|12.||Andrea H, Donna R, Andrej J, Jerrold O. Female Rats Do Not Exhibit Free Fatty Acid- Induced Insulin Resistance. Diabetes 2002;51:1907-12. |
|13.||Raphael KR, Sabu MC, Kuttan B. Hypoglycaemic effect of methanol extract of Phyllanthus amarus Schum and Thonn on alloxan induced diabetes mellitus in rats and its relation with antioxidant potential. Indian J Exp Biol 2002;40:905-9. |
|14.||Dhanabal SP, Kokate CK, Ramanathan M, Kumar EP, Suresh B.Hypoglycaemic activity of Pterocarpus marsupium Roxb.th Phytother Res 2006;20:4-8. |
|15.||Ortiz-Andrade RR, Garcνa-Jimιnez S, Castillo-Espaρa P, Ramνrez-Avila G, Villalobos-Molina R, Estrada-Soto. Alpha-Glucosidase inhibitory activity of the methanolic extract from Tournefortia hartwegiana: An anti-hyperglycemic agent. J Ethnopharmacol 2007;109:48-53. |
|16.||Kim SH, Hyun SH, Choung SY. Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. J Ethnopharmacol 2006;104:119-23. [PUBMED] [FULLTEXT]|
|17.||Haffner SM. Management of Dyslipidemia in Adults with Diabetes. Diabetes Care 2003;26:S83-6. |
|18.||Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. [PUBMED] [FULLTEXT]|
|19.||Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA.Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56:374-7. [PUBMED] [FULLTEXT]|
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits
| ||Makula Chandra Sekhar, P. Jaya Chandra Reddy |
| ||Molecular and Cellular Biochemistry. 2012; 364(1-2): 159 |
|[VIEW] | [DOI]|